Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pathogenesis of systemic sclerosis: a vascular hypothesis.

× No keyword cloud information.

76 in total

Review 1. The pathogenesis, diagnosis and treatment of Raynaud phenomenon.

Authors: Ariane L Herrick
Journal: Nat Rev Rheumatol Date: 2012-07-10 Impact factor: 20.543

Review 2. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis.

Authors: Maria Trojanowska
Journal: Nat Rev Rheumatol Date: 2010-06-29 Impact factor: 20.543

3. Investigation of anal function in patients with systemic sclerosis.

Authors: A L Herrick; J D Barlow; A Bowden; N Williams; A R Hobson; M Irving; M I Jayson
Journal: Ann Rheum Dis Date: 1996-06 Impact factor: 19.103

4. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting.

Authors: C G Kallenberg; A A Wouda; M H Hoet; W J van Venrooij
Journal: Ann Rheum Dis Date: 1988-08 Impact factor: 19.103

Review 5. Interstitial lung disease in systemic sclerosis.

Authors: Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal: Lung Date: 2007 Jul-Aug Impact factor: 2.584

6. Serum YKL-40 and IL-6 levels correlate with ultrasound findings of articular and periarticular involvement in patients with systemic sclerosis.

Authors: Rositsa Karalilova; Maria Kazakova; Tanya Sapundzhieva; Valentin Dichev; Zguro Batalov; Victoria Sarafian; Anastas Batalov
Journal: Rheumatol Int Date: 2019-08-02 Impact factor: 2.631

Pathogenesis of systemic sclerosis: a vascular hypothesis.

Review 1. The pathogenesis, diagnosis and treatment of Raynaud phenomenon.

Review 2. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis.

3. Investigation of anal function in patients with systemic sclerosis.

4. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting.

Review 5. Interstitial lung disease in systemic sclerosis.

6. Serum YKL-40 and IL-6 levels correlate with ultrasound findings of articular and periarticular involvement in patients with systemic sclerosis.

7. Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis.

8. A controlled trial of antihypertensive therapy in systemic sclerosis (scleroderma).

9. Blood hyperviscosity with reduced skin blood flow in scleroderma.

10. Distribution of macrovascular disease in scleroderma.